PCSK9-targeted therapies
PCSK9-targeted therapies has been studied in 4 papers since 2026: 3 observational studies in people, 1 review; 4 in the past year. The newest paper, Nov 2, 2026: “Comparative Cardiovascular Outcomes Across PCSK9-Targeted Therapies: A Real-World Matched Cohort Analysis of Inclisiran, Alirocumab, and Evolocumab”.
4 papers study it9 findingsUpdated
3 new papers in 30 daysSee all 4 papers on PCSK9-targeted therapies
At a glance
The findings reach people, from one lab or study. 3 independent labs in 2 countries.
“PCSK9-targeted therapy significantly reduced the risk of all-cause stroke (OR, 0.78 (95% CI: 0.68-0.90), P < 0.001)”
None of its findings points the other way.
- 3 independent labs in 2 countries
- Humans3
Studies in people
1 study gave PCSK9-targeted therapies to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Lowers the risk of strokeOR 0.78 (95% CI 0.68-0.90) down: Lowers the risk of ischemic strokeOR 0.77 (95% CI 0.63-0.94) no change: Has no effect on hemorrhagic strokeOR 1.16 (95% CI 0.70-1.93) | Review of trials | 64,116 people pooled | The American journal of medicine, Aug 4, 2026 |
What did studies of PCSK9-targeted therapies find?
3Studies of PCSK9-targeted therapies measured 3 outcomes: Parkinson's disease, dementia and hemorrhagic stroke.
Parkinson's disease
no changein humans1OR 0.82
1 study
Parkinson's disease
no changein humans1OR 0.82
PCSK9-targeted therapies showed no clear effect on Parkinson's disease in humans (OR 0.82 (95% CI 0.11-6.37)).
“no significant association was observed for the risk of dementia and Parkinson's disease”
Human trialn = 64,116
The American journal of medicine
Dementia
no changein humans1OR 0.77
1 study
Dementia
no changein humans1OR 0.77
PCSK9-targeted therapies showed no clear effect on dementia in humans (OR 0.77 (95% CI 0.14-4.28)).
“no significant association was observed for the risk of dementia and Parkinson's disease”
Human trialn = 64,116
The American journal of medicine
Hemorrhagic stroke
no changein humans1OR 1.16
1 study
Hemorrhagic stroke
no changein humans1OR 1.16
PCSK9-targeted therapies showed no clear effect on hemorrhagic stroke in humans (OR 1.16 (95% CI 0.70-1.93)).
“no significant association was observed for the risk of hemorrhagic stroke (OR, 1.16 (95%CI: 0.70-1.93), P = 0.56)”
Human trialn = 64,116
The American journal of medicine
What is PCSK9-targeted therapies linked with?
6Studies link PCSK9-targeted therapies with 6 measures, among them acute myocardial infarction, mortality and major adverse cardiovascular events.
Acute myocardial infarction
mixedin humans1
1 study
Acute myocardial infarction
mixedin humans1
PCSK9-targeted therapies are associated with acute myocardial infarction in humans (Atherosclerotic heart disease and dyslipidemia; compared with no PCSK9 inhibitor use).
“AMI was lower at 1 year but not consistently thereafter.”
HumansAtherosclerotic heart disease and dyslipidemia; compared with no PCSK9 inhibitor use1, 3, and 5 years
AHA Scientific Sessions 2026 abstract
Mortality
downin humans1HR 0.323
1 study
Mortality
downin humans1HR 0.323
PCSK9-targeted therapies are associated with mortality in humans (1 year: HR 0.323 (95% CI 0.305–0.341); 3 years: HR 0.432 (0.416–0.448); 5 years: HR 0.467 (0.451–0.483)).
“All-cause mortality was lower at 1 year (HR 0.323, 95% CI 0.305-0.341)”
HumansAtherosclerotic heart disease and dyslipidemia; compared with no PCSK9 inhibitor use; possible residual confounding1, 3, and 5 years
AHA Scientific Sessions 2026 abstract
Major adverse cardiovascular events
downin humans1HR 0.857
1 study
Major adverse cardiovascular events
downin humans1HR 0.857
PCSK9-targeted therapies are associated with major adverse cardiovascular events in humans (Atherosclerotic heart disease and dyslipidemia; compared with no PCSK9 inhibitor use) (1 year: HR 0.857 (95% CI 0.837–0.878); 3 years: HR 0.946 (0.927–0.965); 5 years: HR 0.969 (0.950–0.989)).
“After matching, PCSK9 therapy was associated with significantly lower MACE at 1 year”
HumansAtherosclerotic heart disease and dyslipidemia; compared with no PCSK9 inhibitor use1, 3, and 5 years
AHA Scientific Sessions 2026 abstract
LDL cholesterol
downin humans1−48% average ldl-c reduction
1 study
LDL cholesterol
downin humans1−48% average ldl-c reduction
PCSK9-targeted therapies are associated with LDL cholesterol in humans (PCSK9-targeted treatment with background oral lipid-lowering therapy) (-48% average LDL-c reduction).
“While the average LDL-c reduction was -48% across the entire cohort, results differed widely according to adherence”
HumansPCSK9-targeted treatment with background oral lipid-lowering therapyMedian 15 months70% malesn = 403
ESC Congress 2026 abstract
Ischemic stroke
downin humans1OR 0.77
1 study
Ischemic stroke
downin humans1OR 0.77
PCSK9-targeted therapies lower the risk of ischemic stroke in humans (OR 0.77 (95% CI 0.63-0.94)).
“PCSK9-targeted therapy significantly reduced the risk of all-cause stroke (OR, 0.78 (95% CI: 0.68-0.90), P < 0.001) and ischemic stroke (OR, 0.77 (95% CI: 0.63-0.94), P = 0.01)”
Human trialn = 64,116
The American journal of medicine
Stroke
downin humans1OR 0.78
1 study
Stroke
downin humans1OR 0.78
PCSK9-targeted therapies lower the risk of stroke in humans (OR 0.78 (95% CI 0.68-0.90)).
“PCSK9-targeted therapy significantly reduced the risk of all-cause stroke (OR, 0.78 (95% CI: 0.68-0.90), P < 0.001)”
Human trialn = 64,116
The American journal of medicine